Literature DB >> 16873097

Intracellular Th1/Th2 balance of pulmonary CD4(+) T cells in patients with active interstitial pneumonia evaluated by serum KL-6.

Yasuo Shimizu1, Hidemasa Kuwabara, Akihiro Ono, Seiichi Higuchi, Takeshi Hisada, Kunio Dobashi, Mitsuyoshi Utsugi, Yoshinori Mita, Masatomo Mori.   

Abstract

The balance between CD4(+) T helper (Th1) lymphocytes producing interferon-gamma or Interleukin-4 (Th2) in the lungs may vary among diseases and during the progression of interstitial pneumonia (IP). Both idiopathic pulmonary fibrosis (IPF) and collagen vascular diseases (CVD) are associated with IP, but the clinical course and the response to treatment are different. Since Th1 or Th2 modulating drugs have been proven to alter the lymphocyte balance in vitro, it is important to elucidate the Th1/Th2 profile in patients with active IP. Bronchoalveolar lavage (BAL) was performed in patients who had IPF (n = 12) or CVD (n = 12) with IP, as well as in patients who had bronchoectasis and bronchopneumonia (n = 12). The CVD patients had rheumatoid arthritis (n = 6), Sjogren's syndrome (n = 2), dermatomyositis (n = 1), progressive systemic sclerosis (n = 2), and CREST syndrome (n = 1) as the underlying diseases. IP activity was evaluated by measuring serum KL-6, which is a clinically useful indicator for IP. The Th1/ Th2 balance and the CD4(+)/CD8(+) ratio were determined for lymphocytes obtained from BAL by flow cytometric analysis. In IPF patients, the CD4(+)/CD8(+) ratio was lower than in CVD patients. IPF patients showed Th2 dominance and CVD patients showed Th1 dominance when IP was active as evaluated by the serum KL-6 level. These data indicated that the Th1/Th2 balance of CD4(+) T cells in the BAL differs between active IPF and CVD, even though KL-6 is elevated in both diseases. Therefore, the Th1/Th2 profile should be investigated to determine the use of Th1/Th2 modulator therapy for active IP with elevation of KL-6.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16873097     DOI: 10.1080/08923970600809389

Source DB:  PubMed          Journal:  Immunopharmacol Immunotoxicol        ISSN: 0892-3973            Impact factor:   2.730


  11 in total

1.  Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis.

Authors:  Anagha A Divekar; Dinesh Khanna; Fereidoun Abtin; Paul Maranian; Rajeev Saggar; Rajan Saggar; Daniel E Furst; Ram Raj Singh
Journal:  Clin Immunol       Date:  2011-09-05       Impact factor: 3.969

2.  Cytokine-like factor 1 gene expression is enriched in idiopathic pulmonary fibrosis and drives the accumulation of CD4+ T cells in murine lungs: evidence for an antifibrotic role in bleomycin injury.

Authors:  Daniel J Kass; Guoying Yu; Katrina S Loh; Asaf Savir; Alain Borczuk; Rehan Kahloon; Brenda Juan-Guardela; Giuseppe Deiuliis; John Tedrow; Jiin Choi; Thomas Richards; Naftali Kaminski; Steven M Greenberg
Journal:  Am J Pathol       Date:  2012-03-16       Impact factor: 4.307

3.  Different profiles of notch signaling in cigarette smoke-induced pulmonary emphysema and bleomycin-induced pulmonary fibrosis.

Authors:  Shi Li; Xiaofei Hu; Zheng Wang; Meng Wu; Jinnong Zhang
Journal:  Inflamm Res       Date:  2015-03-27       Impact factor: 4.575

4.  Pulmonary vaccination as a novel treatment for lung fibrosis.

Authors:  Samuel L Collins; Yee Chan-Li; Robert W Hallowell; Jonathan D Powell; Maureen R Horton
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

5.  Genetic susceptibility to interstitial pulmonary fibrosis in mice induced by vanadium pentoxide (V2O5).

Authors:  Dianne M Walters; Kevin M White; Ushma Patel; Martin J Davis; Roberta M Veluci-Marlow; Solomon Raju Bhupanapadu Sunkesula; James C Bonner; Jessica R Martin; Wes Gladwell; Steven R Kleeberger
Journal:  FASEB J       Date:  2013-11-27       Impact factor: 5.191

6.  Molecular and cellular mechanisms of pulmonary fibrosis.

Authors:  Nevins W Todd; Irina G Luzina; Sergei P Atamas
Journal:  Fibrogenesis Tissue Repair       Date:  2012-07-23

7.  In-air microparticle induced X-ray emission analysis of particles in interstitial pneumonia lung tissue obtained by transbronchial biopsy.

Authors:  Yasuo Shimizu; Shinichi Matsuzaki; Takahiro Satoh; Masashi Koka; Akihito Yokoyama; Takeru Ohkubo; Yasuyuki Ishii; Tomihiro Kamiya; Makoto Fueki; Masatomo Mori; Kunio Dobashi
Journal:  J Clin Biochem Nutr       Date:  2011-07-13       Impact factor: 3.114

Review 8.  Pivotal roles of GM-CSF in autoimmunity and inflammation.

Authors:  Aoi Shiomi; Takashi Usui
Journal:  Mediators Inflamm       Date:  2015-03-08       Impact factor: 4.711

9.  Serum markers in interstitial pneumonia with and without Pneumocystis jirovecii colonization: a prospective study.

Authors:  Yasuo Shimizu; Noriaki Sunaga; Kunio Dobashi; Makoto Fueki; Naoto Fueki; Sohei Makino; Masatomo Mori
Journal:  BMC Infect Dis       Date:  2009-04-22       Impact factor: 3.090

10.  Phenotypes of Peripheral Blood Lymphocytes and Cytokine Expression in Polymyositis and Dermatomyositis before Treatment and after Clinical Remission.

Authors:  Yasuhiro Shimojima; Wataru Ishii; Masayuki Matsuda; Shu-Ichi Ikeda
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2012-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.